Literature DB >> 9130690

Studies of decitabine with allogeneic progenitor cell transplantation.

S Giralt1, M Davis, S O'Brien, K van Besien, R Champlin, D de Vos, H Kantarjian.   

Abstract

The aim was to determine the efficacy and safety of decitabine in the settings of relapse post-allogeneic progenitor cell transplantation or as part of the conditioning regimen. Three patients (two AML, one ALL) received single agent decitabine 1000 mg/m2 total dose) for treatment of relapse post-transplant (group 1). Median age was 32 years. Median time to relapse was 7 months. In another study four patients (three CML in an accelerated phase, one AMML) received decitabine 400 mg/m2, with busulfan 12 mg/kg and cyclophosphamide 100 mg/kg as conditioning for allogeneic stem cell transplantation (group 2). Median age was 42 years; median time to transplant was 5 months. All patients received at least 4 x 10(6) CD34+ cells from their HLA compatible donors. All patients in group 1 achieved complete remissions after decitabine therapy. The median time to neutrophil and platelet recovery were 24 and 23 days, respectively. Two patients required reinfusion of donor cells because of delayed engraftment. One patient remains alive and in remission 160 days post-decitabine therapy. Two patients in group 2 engrafted on days 23 and 25. Two patients required reinfusion of stem cells because of lack of neutrophil recovery by day 21. Two patients achieved complete cytogenetic and hematologic remission. Three patients are alive at 167,129, and 109 days post-transplant. One patient died of progressive Pseudomonas cellulitis 54 days post-initial infusion. Decitabine therapy is well tolerated in the setting of allogeneic stem cell transplantation, initial results in patients relapsing after transplant are encouraging and warrant further studies. The causes of delayed engraftment after single agent or combination therapy need to be better explored. The existence of active metabolites of decitabine which may still be present in the blood at the time of stem cell infusions, and/or insufficient immunosuppression of the preparative regimen are being explored as possible explanations for this phenomenon.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9130690

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

Review 1.  Promising approaches in acute leukemia.

Authors:  J Cortes; H M Kantarjian
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

2.  Decitabine for relapsed acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.

Authors:  Jie-Ke Cui; Yin Xiao; Yong You; Wei Shi; Qing Li; Yi Luo; Lin Jiang; Zhao-Dong Zhong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-10-20

3.  Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation.

Authors:  Xiaowen Tang; Benigno C Valdez; Yunju Ma; Qianqian Zhang; Changju Qu; Haiping Dai; Jia Yin; Zheng Li; Ting Xu; Yang Xu; Jia Chen; Xiaming Zhu; Zixing Chen; Depei Wu; Borje S Andersson
Journal:  Bone Marrow Transplant       Date:  2021-02-26       Impact factor: 5.483

4.  Epigenetic therapy in allogeneic hematopoietic stem cell transplantation.

Authors:  Qaiser Bashir; Basem Magdy William; Guillermo Garcia-Manero; Marcos de Lima
Journal:  Rev Bras Hematol Hemoter       Date:  2013

5.  Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy.

Authors:  Metin Karahoca; Richard L Momparler
Journal:  Clin Epigenetics       Date:  2013-02-01       Impact factor: 6.551

6.  Epigenetic approaches in stem cell transplantation.

Authors:  Nicole Engel
Journal:  Clin Epigenetics       Date:  2011-07-16       Impact factor: 6.551

7.  Immune responses to azacytidine in animal models of inflammatory disorders: a systematic review.

Authors:  Sija Landman; Chiel van der Horst; Piet E J van Erp; Irma Joosten; Rob de Vries; Hans J P M Koenen
Journal:  J Transl Med       Date:  2021-01-06       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.